1. Rotonya M. Carr, Amanke Oranu, and Vandana Khungar. Non-alcoholic fatty liver disease: Pathophysiology and management. MScGastroenterol Clin North Am. 2016 Dec; 45(4): 639-652. doi: 10.1016/j.gtc.2016.07.003
2. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402.
3. ICD-11 Implementation or Transition Guide, Geneva: World Health Organization; 2019; License: CCBY-NC-SA3.0IGO.
4. Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. Journal of Hepatology. (2020), doi: 10.1016/j.jhep.2020.03.039.
5. Eslam M, Sanyal AJ, George J. MAFLD: a consensus driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020 Feb 8. Doi:10.1053/j. gastro.2019.11.312.
6. Yasser Fouad, et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver International. 2020;00:1-8.
7. Shi Z., Tuomilehto J., et al. The circadian syndrome predicts cardiovascular disease better than metabolic syndrome in Chinese adults. J Intern Med. 2020 Dec 19. PMID: 31081577. PMCID: PMC6851668. DOI: 10.1111 / joim.12924
8. Ribeiro A., Igual-Perez M.-J., Santos Silva E., Sokal E. M. Childhood fructoholism and fructoholic liver disease. Hepatol Commun. 2019;3:44-51. doi:10.1002/ hep4.1291
9. DiStefano J.K., Shaibi G. Q. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatr Obes. 2020 Dec 11: e12759. doi: 10.1111/ ijpo.12759
10. Jegatheesan P, De Bandt J. P. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017;9(3):230. doi: 10.3390/nu9030230
11. Jensen T., Abdelmalek M. F., Sullivan S., et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063-1075. doi: 10.1016/j. jhep.2018.01.019
12. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015 Apr;62(1 Suppl): S47-64. doi: 10.1016/j. jhep.2014.12.012. PMID: 25920090.
13. Day C.P., James O. F. Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 1998;114:842-845.
14. Sharma M., Mitnala S., Vishnubhotla R. K., et al. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. Journal of Clinical and Experimental Hepatology. 2015 Jun;5(2):147-158. DOI: 10.1016/j.jceh.2015.02.002
15. Tilg H., Moschen A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836-1846.
16. Buzzetti E., Pinzani M., Tsochatzis E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism: Clinical and Experimental. 2016, 65(8):1038-1048. DOI: 10.1016/j.metabol.2015.12.012
17. Chelakkot C., Ghim J., Ryu S. H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 50, 103 (2018). Doi: 10.1038/ s12276-018-0126-x
18. Nier A., et al. Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. PLoS One. 2017 Sep 7;12(9): e0183282.
19. Kapil S. et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2016;31:213-221.
20. Philips C.A., Augustine P., Yerol P. K., et al. Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. J Clin Transl Hepatol. 2020;8(1):87-99. doi:10.14218/ JCTH.2019.00035
21. Wijarnpreecha Karn А. et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology. May 2020, Vol. 32, Issue 5, pp. 601-608 doi: 10.1097/MEG.0000000000001541
22. de Faria Ghetti F., et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57(3):861-876.
23. Seliverstov P.V., Sitkin S. I., Radchenko V. G., et al. Saccharomyces boulardii modulates the composition of the gut microbiota in patients with non-alcoholic fatty liver disease, thus preventing the progression of the disease. Experimental and Clinical Gastroenterology. 2018;(2):4-18. (In Russ.)
24. Jiang W., et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.
25. Shen F., et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16(4):375-381.
26. Boursier J, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-775.
27. Elizabeth K. Speliotes et al. Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLoS Genet. 2011 Mar; 7(3): e1001324.
28. Anstee Q.M., Darlay R., Cockell S., Meroni M., et al. Genomewide association study of non-alcoholic fatty liver and ste-atohepatitis in a histologically characterised cohort. Journal of Hepatology. 2020, Vol. 73, Issue 3, pp. 505-515.
29. Pang, J, Xu, W, Zhang, X, et al. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017; 46: 175-182. Doi:10.1111/apt.14119
30. Kurtanov K. A., Sydykova L. A., Pavlova N. I., et al. Polymorphism of the adiponutrin gene (PNPLA3) in the indigenous inhabitants of the Republic of Sakha (Yakutia) with type 2 diabetes mellitus. Almanac of Clinical Medicine. 2018;46(3):258-263. (In Russ.) doi: 10.18786/2072-05052018-46-3-258-263 Куртанов Х. А., Сыдыкова Л. А., Павлова Н. И., Филиппова Н. П., Додохов В. В., Апсолихова Г. А., Соловьева Н. А., Дьяконова А. Т., Неустроева Л. М., Варламова М. А., Борисова Н. В. Полиморфизм гена адипонутрина (PNPLA3) у коренных жителей Республики Саха (Якутия), страдающих сахарным диабетом 2-го типа. Альманах клинической медицины. 2018;46(3):258-263.